Seeking Alpha

Visus (VVUS) +9.45% after saying that sales of its obesity drug Qsymia climbed 68% M/M to almost...

Visus (VVUS) +9.45% after saying that sales of its obesity drug Qsymia climbed 68% M/M to almost 13K prescriptions in the month to Dec 21 and came in well above forecasts. It's a bit of a turnaround for Qsymia after initial sales were disappointing following the drug's approval in the summer. Vivus is due to present at the JPM Healthcare conference later today.
Comments (4)
  • phemale60
    , contributor
    Comments (2776) | Send Message
     
    Doesn't take much to get this stock to move higher - FAST!

     

    Saw it being bought up premarket so knew something was up! Great!!
    7 Jan 2013, 10:05 AM Reply Like
  • vitosoranno1
    , contributor
    Comments (1098) | Send Message
     
    There have been many nay sayers who maintain that a worthwhile market for obesity drugs will not materialize.

     

    If the Vivus sales figures continue to improve, it will be an indicator that Arena's Belviq will also experience astounding sales results when it hits the market in upcoming weeks.

     

    .
    7 Jan 2013, 10:20 AM Reply Like
  • user418
    , contributor
    Comments (196) | Send Message
     
    THE INCREASE IN PRESCRIPTIONS IS DUE TO A FREE TWO WEEKS SUPPLY OF PILLS BY VIVUS.

     

    SHORT VIVUS!!!!!!!!!!!!!!!!!...
    7 Jan 2013, 10:54 AM Reply Like
  • phemale60
    , contributor
    Comments (2776) | Send Message
     
    You know the old saying: "The first one is free"!! In this case could be a good thing -- need to try out first to assure side effects are not as scary as many led to believe by the hypers for competitors. ARNA holders kind of hurting themselves by vilifying VVUS!
    7 Jan 2013, 12:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|